Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Short Interest Update

by · The Markets Daily

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 240,300 shares, a growth of 92.9% from the December 15th total of 124,600 shares. Based on an average daily volume of 911,500 shares, the short-interest ratio is presently 0.3 days.

Ekso Bionics Stock Performance

NASDAQ EKSO traded down $0.02 during trading hours on Tuesday, reaching $0.69. The company’s stock had a trading volume of 645,723 shares, compared to its average volume of 6,737,727. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. The business has a 50-day simple moving average of $0.70 and a 200 day simple moving average of $0.96. Ekso Bionics has a 52 week low of $0.50 and a 52 week high of $2.50. The stock has a market cap of $15.27 million, a PE ratio of -1.07 and a beta of 1.47.

Ekso Bionics (NASDAQ:EKSO – Get Free Report) last issued its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The business had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. During the same period in the prior year, the business earned ($0.24) EPS. Equities research analysts predict that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on EKSO. Lake Street Capital reduced their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. StockNews.com assumed coverage on shares of Ekso Bionics in a report on Tuesday. They issued a “hold” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Ekso Bionics in a report on Tuesday.

Check Out Our Latest Analysis on Ekso Bionics

Ekso Bionics Company Profile

(Get Free Report)

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.

See Also